Comparative Pharmacology
Head-to-head clinical analysis: AVYCAZ versus CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVYCAZ versus CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER.
AVYCAZ vs CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AVYCAZ is a combination of ceftazidime, a cephalosporin beta-lactam antibiotic, and avibactam, a non-beta-lactam beta-lactamase inhibitor. Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis. Avibactam protects ceftazidime from degradation by certain beta-lactamases, including Ambler class A, class C, and some class D enzymes.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1 vial (ceftazidime 2g and avibactam 0.5g) IV over 2 hours every 8 hours.
750 mg to 1.5 g intravenously every 8 hours; for severe infections, up to 1.5 g every 6 hours.
None Documented
None Documented
Ceftazidime: ~2.8 hours; avibactam: ~2.7 hours. Extended in renal impairment (e.g., CrCl <50 mL/min requires dose adjustment).
Terminal elimination half-life: 1.2-1.6 hours (prolonged to 15-22 hours in severe renal impairment, CrCl <10 mL/min); requires dose adjustment in renal failure
Ceftazidime: primarily renal (80-90% unchanged); avibactam: primarily renal (85-95% unchanged). Fecal excretion <1%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic